news flash·2025-06-30 11:00Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has signed a licensing agreement with FBD to collaborate on the development, production, and commercialization of the SIRPα-Fc fusion protein (HCB101) and related drugs in specified regions and fields [1] Group 1: Licensing Agreement Details - The agreement involves Fosun Pharma's subsidiary paying up to $59 million to FBD [1] - Additionally, Fosun Pharma will pay up to $143 million in commercial milestone payments based on the annual net sales of the licensed product in Region 1 [1] Group 2: Market Considerations - The sales performance of the licensed product may be influenced by factors such as drug demand, market competition, and sales channels, indicating potential uncertainties [1]